Dataset from A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects

The purpose of this trial is to assess the non-inferior antiviral activity of GSK1349572 50
mg plus Abacavir/Lamivudine once daily versus Efavirenz/Emtricitabine/Tenofovir disoproxil
fumarate (ATRIPLA® a trade mark of Bristol-Myers Squibb and Gilead Sciences LLC) over 48
weeks; non-inferiority will also be tested at Week 96. This study will be conducted in HIV-1
infected ART-naïve adult subjects. Long term antiviral activity, tolerability, safety, and
development of viral resistance will be evaluated.